Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SBTX.LSE
- Price
- 25.00
- Stock movement up
- +- (%)
- Company name
- SkinBioTherapeutics PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.71B
- Ent value
- 5.71B
- Price/Sales
- 20607.59
- Price/Book
- 1564.18
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 19.36%
- 1 year return
- 150.00%
- 3 year return
- -9.29%
- 5 year return
- 31.95%
- 10 year return
- -
Last updated: 2025-04-04
DIVIDENDS
SBTX.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 20607.59 |
| Price to Book | 1564.18 |
| EV to Sales | 20599.37 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 228.44M |
| EPS (TTM) | -0.03 |
| FCF per share (TTM) | -0.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 277.13K |
| Gross profit (TTM) | 89.97K |
| Operating income (TTM) | -5.06M |
| Net income (TTM) | -4.81M |
| EPS (TTM) | -0.03 |
| EPS (1y forward) | -0.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 32.47% |
| Operating margin (TTM) | -1826.29% |
| Profit margin (TTM) | -1736.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.84M |
| Net receivables | 164.56K |
| Total current assets | 3.29M |
| Goodwill | 0.00 |
| Intangible assets | 761.17K |
| Property, plant and equipment | 160.41K |
| Total assets | 4.21M |
| Accounts payable | 463.29K |
| Short/Current long term debt | 97.05K |
| Total current liabilities | 500.65K |
| Total liabilities | 560.34K |
| Shareholder's equity | 3.65M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.51M |
| Capital expenditures (TTM) | 241.76K |
| Free cash flow (TTM) | -4.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -131.81% |
| Return on Assets | -114.27% |
| Return on Invested Capital | -130.47% |
| Cash Return on Invested Capital | -128.76% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 24.75 |
| Daily high | 25.42 |
| Daily low | 24.20 |
| Daily Volume | 1.33M |
| All-time high | 75.50 |
| 1y analyst estimate | 56.00 |
| Beta | 1.75 |
| EPS (TTM) | -0.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SBTX.LSE | S&P500 | |
| Current price drop from All-time high | -66.89% | -12.44% |
| Highest price drop | -90.40% | -56.47% |
| Date of highest drop | 21 Mar 2024 | 9 Mar 2009 |
| Avg drop from high | -49.60% | -11.07% |
| Avg time to new high | 56 days | 12 days |
| Max time to new high | 975 days | 1805 days |
COMPANY DETAILS
Marketcap
5.71B
Marketcap category
Mid-cap
Description
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
Employees
11
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found